Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belcesiran in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
NCT04764448Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Feb 2021
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Antisense DNA, Gene Silencing
- Countries
- 14
01
Overview
A Phase 2 trial of belcesiran in alpha-1 antitrypsin deficiency (AATD), sponsored by Novo Nordisk. Started Feb 2021; status: terminated.
02
Drugs
belcesiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT04764448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764448.